Camp4 Therapeutics CORP 8-K filings

CAMP4 Therapeutics announced Q2 2026 results, highlighting regulatory clearance for its CMP-002 Phase 1/2 trial in SYNGAP1 patients and securing $50.1 million in funding, extending cash runway to end of 2028.

CAMP4 Therapeutics announced the second closing of its private placement, raising approximately $50.1 million to advance its CMP-002 program for SYNGAP1-related disorder.

CAMP4 Therapeutics receives Australian regulatory clearance to initiate its Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder, and is eligible for up to $50 million in additional funding.

CAMP4 Therapeutics announced new preclinical data showing CMP-002 significantly improves seizure phenotypes in a SYNGAP1-related disorder mouse model, advancing towards a Phase 1/2 trial.

CAMP4 Therapeutics announced first quarter 2026 financial results, highlighting significant progress in its CMP-002 clinical development and a cash runway extending into 2028.

CAMP4 Therapeutics Corporation announced the appointment of Michael MacLean, a seasoned financial leader in the biotechnology industry, as a Class III director, effective April 1, 2026.

CAMP4 Therapeutics announced full year 2025 financial results, highlighted progress in its SYNGAP1 program, a new strategic collaboration with GSK, and strengthened its balance sheet with new financing extending its cash runway into 2028.

CAMP4 Therapeutics has updated its corporate presentation, providing the investment community with the latest business overview.

CAMP4 Therapeutics Corporation is relocating its laboratory and office operations to a larger facility in Watertown, Massachusetts, while terminating its current Cambridge lease early.

CAMP4 Therapeutics Corporation has entered into an underwriting agreement for a public offering of 5 million common shares at $6.00 each, aiming to raise approximately $28 million in net proceeds to fund its operations.

CAMP4 Therapeutics and GSK have entered a strategic collaboration to develop antisense oligonucleotide (ASO) therapeutics for neurodegenerative and kidney diseases, with CAMP4 receiving an upfront payment and potential milestones.

CAMP4 Therapeutics reported Q3 2025 financial results, initiated GLP toxicology studies for CMP-002, and secured $50 million in private placement funding.

CAMP4 Therapeutics has initiated GLP toxicology studies for its lead candidate CMP-SYNGAP-01, a critical step towards a first-in-human clinical trial for SYNGAP1-related disorders.

CAMP4 Therapeutics announced an oversubscribed private placement of up to $100 million to fund its SYNGAP1 program and key management changes.

CAMP4 Therapeutics announced its second quarter 2025 financial results and provided positive updates on its SYNGAP1 and UCDs clinical programs.

CAMP4 Therapeutics Corporation announced the successful election of its Class I directors and the ratification of Ernst & Young LLP as its independent auditor at its 2025 annual meeting of stockholders.

CAMP4 Therapeutics shares positive translational data for its SYNGAP1-related disorders program and preclinical/clinical data for its Urea Cycle Disorders program at the American Society of Gene and Cell Therapy Annual Meeting.

CAMP4 Therapeutics announced its Q1 2025 financial results, highlighting progress in clinical trials and a milestone payment from Fulcrum Therapeutics.

CAMP4 Therapeutics announced its full year 2024 financial results, provided a corporate update, and highlighted the progress of its clinical programs and research collaborations.

Camp4 Therapeutics Corporation announced the appointment of Douglas Williams and Murray Stewart to its Board of Directors, effective March 17, 2025, expanding the board's size to twelve members.

Camp4 Therapeutics announced favorable safety results from its Phase 1 clinical trial of CMP-CPS-001 for urea cycle disorders and highlighted key upcoming milestones for 2025.

CAMP4 Therapeutics completed its IPO, raised $82.1 million, and advanced its lead program while entering a significant research collaboration with BioMarin.

CAMP4 Therapeutics Corporation completed its initial public offering (IPO) on October 15, 2024, and filed an amended and restated certificate of incorporation and bylaws.